Trever Bivona, M.D., Ph.D. | American Lung Association

Location Select your location

Trever Bivona, M.D., Ph.D.

University of California, San Francisco
Funded by the American Lung Association of the Upper Midwest
Defining New Targeted Therapy Approach for Lung Cancer Mutation

Treatments that specifically target proteins that drive cancer growth, such as RAF, MEK, ALK, and EGFR inhibitors, are leading to improved responses in many advanced-stage lung cancer patients. However, not all patients benefit from this new targeted treatment approach. We will focus on defining a new targeted therapy approach for patients with a certain form of lung cancer caused by mutation of a gene called NF1. Recent studies have identified more than 140 different mutations in NF1 in non-small cell lung cancer (NSCLC). These mutations occur in about 10 percent of NSCLC patients. Findings from our studies could lead to treatments that are more effective for the many lung cancer patients with this aggressive, NF1-mutant form of the disease.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.